Stay updated on BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Sign up to get notified when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.

Latest updates to the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0 on the page.SummaryDifference0.1%

- Check23 days agoChange DetectedRemoved the government funding lapse notice from the page; no other content changes were made. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check45 days agoChange DetectedThe screenshots indicate cosmetic/UI adjustments with no changes to core study details (eligibility criteria, primary outcomes, or status). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check66 days agoChange DetectedIntroducing a major operational notice about funding status and updated versioning to v3.2.0, while removing the previous v3.1.0 reference.SummaryDifference4%

- Check74 days agoChange DetectedUpdated the page from Revision: v3.0.2 to Revision: v3.1.0, signaling a new software version.SummaryDifference0.1%

- Check88 days agoChange DetectedUpdate to v3.0.2 replacing v3.0.1; removal of the 'Back to Top' link; no other substantive changes.SummaryDifference0.2%

Stay in the know with updates to BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BBP-398 + Osimertinib in EGFR+ NSCLC: Clinical Trial page.